GSK lung cancer drug Ris-Rez extends patient survival in China study
(Alliance News) - GSK PLC on Sunday said Ris-Rez cut the risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China.
Along with Lianyungang, China-headquartered licensor Hansoh Pharmaceutical Group Co Ltd, the London-based pharmaceutical company reported positive results from the Artemis-008 phase three trial evaluating the B7-H3-targeted antibody-drug conjugate risvutatug rezetecan, also known as Ris-Rez.
"In the trial, Ris-Rez reduced the risk of death by 54% compared with topotecan, a commonly used treatment option following progression on first-line therapy, meeting the trial's primary endpoint after a median follow-up of 12.2 months," GSK said.
The patients who received Ris-Rez lived a median of 18.5 months, while those receiving topotecan lived for 10.3 months.
Hesham Abdullah, senior vice president, global head of Oncology, Research & Development, said: "These results add to the growing body of evidence for Ris-Rez and mark an important step forward for our lung cancer portfolio. The significant improvement in survival observed in this study, together with an encouraging safety profile, provide further momentum for GSK's global development of Ris-Rez across later-line and earlier treatment settings for small cell lung cancer."
GSK shares closed down 0.3% at 1,770.50 pence each in London on Friday.
By Elijah Dale, Alliance News senior reporter Asia-Pacific
Comments and questions to newsroom@alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
More In Markets
The Euro Has a French Problem. How Low Can the Currency Go?
Morningstar DBRS: Have European Banks Broken the Sovereign Doom Loop, or Just Reshaped It?
